The sepsis diagnostics market was valued at USD 550 million in 2020 and is expected to reach USD 975 million in 2026 by registering the CAGR of 9.8% during the forecast period.
The coronavirus disease 2019 has proved to wreak havoc to health system leaders throughout the world. The healthcare systems across the world are witnessing an advanced health system stretched beyond its capacity. For instance, according to The Society of Critical Care Medicine, in late 2020 the outbreak of COVID-19 has generated a concern that critically ill patients may overwhelm existing ICU bed availability. If the infection curve is not flattened and the pandemic is concentrated in a 6-month period, that would leave a capacity gap of 1,373,248 inpatient beds and 295,350 ICU beds. This surge in hospital admission for the past year has increased the risk of hospital-acquired infection and the health providers are adopting all the protocols and tests to restrain the infection, which is expected to boost the market growth.
The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. As per the data published by the World Health Organization (WHO) in April 2018, sepsis affects more than 30 million people globally, and over 6 million deaths every year are caused by sepsis. As per the same data, around 3 million newborns and 1.2 million children suffer from this condition every year.
In the present scenario, most of the existing sepsis diagnostic tests can take up to 72 hours or more to process and provide results. Thus, there is a high unmet need for more efficient and rapid diagnostic tests in the market for early diagnosis of this life-threatening condition that could save thousands of lives. Also, there has been increase in regulatory approval and the introduction of technologically advanced diagnostic solutions to leverage unmet opportunities. For instance, in April 2019, Beckman Coulter Inc., a subsidiary of Danaher Corporation received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Early Sepsis Indicator. Earlier in May 2018, T2 Biosystems, Inc. also received the FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. Thus, the rise in hospital-acquired infections and robust product development by the players are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.
Key Market Trends
Molecular Diagnostics Segment, by Technology, is Expected to grow the Fastest over the Forecast Period.
As per the Canadian Medical Association, in December 2020, the most common complications associated with COVID-19 were pneumonia, respiratory failure, kidney failure, and sepsis or systemic inflammation, consistent with other studies. The absolute risk of someone with COVID-19 having sepsis was estimated to be approximately 10.4%. Researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of the market.
Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics. Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in April 2019, GenMark Diagnostics, Inc. received the FDA clearance for its new panel assay, developed to detect gram-negative bacteria causing sepsis. The well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and a rising awareness for early disease diagnosis are expected to drive the market’s growth.
North America is Expected to Hold Largest Share of the Market
COVID-19 has increased the overall risk of sepsis among the global population. The Global Sepsis Alliance stated that COVID-19 could cause sepsis, causing an overwhelming and life-threatening physiological response to an infection that can lead to organ damage and death. In the United States, one in three COVID-19 patients who dies in a hospital dies of sepsis. Owing to this high susceptibility to the disease in this region, the market is expected to grow in the future.
North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the CDC statistics in 2018, sepsis affects more than a million Americans every year and leads to 15% to 30% deaths in the United States. Furthermore, the number of sepsis cases is rising every year in the country due to factors, such as the rise in the geriatric population, infections that are incurable by antibiotics, and higher risks of the disease among people who have undergone an organ transplant. The National Institutes of Health supports many studies that are focused on sepsis, which evaluate various potential treatments for the disease. CDC launched the ‘Get Ahead of Sepsis’, which is an educational initiative to protect Americans from the effect of sepsis. This initiative calls on healthcare professionals to educate patients, prevent infections, identify and diagnose sepsis at an early stage, and start sepsis treatment fast. Emerging technologies linked with an enhanced understanding of the immature and developing neonatal immune system responses to early infection provide an opportunity to develop critically needed biomarkers to improve early identi?cation in this high-risk population. So, the increasing prevalence of sepsis and government initiatives may augment the growth of the market studied.
The market studied is moderately consolidated owing to the presence of a few key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, Immunexpress Inc., Diasorin, Response Biomedical Corp., T2 Biosystems, Inc., and Thermo Fisher Scientific.
The market estimate (ME) sheet in Excel format 3 months of analyst support
Our reports have been used by over 10K customers, including:
The frozen tissues samples market is projected to reach US$ 105,045.91 Thousand by 2028 from US$ 44,399.07 Thousand in 2021; it is estimated to grow at a CAGR of 13.1% during 2021-2028. The report highlights trends prevailing in the market and the factors driving it.The growth of the frozen tissues samples market is attributed to the...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.